Migraine Without Aura Clinical Trial
Official title:
Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine
This study recruits 30 subjects into three groups, including two experimental groups and one control group. The two experimental groups receive acupuncture treatment for 4 weeks and two times functional magnetic resonance imaging scans as well as clinical symptom assessments. The control group receive one scan without any intervention. The aim of this study is to find the whether the effect of acupuncture treatment have diversity among migraineurs with different disease course.
This study recruits 10 patients with long course (> 5 years) without aura migraine, 10 patients with short course (< 5 years) without aura migraine and 10 healthy volunteers who meet the inclusion and exclusion criteria. Among the study, two migraine patient groups receive acupuncture treatment for 4 weeks, the frequency is 30 minutes each time, three times a week. According to the national standard of the people's Republic of China (GB / T 12346-2006) acupoint name and location, the acupuncture treatment includes SJ23 (Si Zhu Kong, unilateral), GB8 (Shuai Gu, unilateral), EX-HN5 (Tai Yang, unilateral), GB20 (Feng Chi, unilateral), LI4 (He Gu, bilateral), GB41 (Zu Lin Qi, bilateral), GB34 (Yang Ling Quan, bilateral) and SJ5 (Wai Guan, bilateral) acupoints. Both migraine patients receive scan in functional magnetic resonance imaging (Siemens 3.0T superconducting magnetic resonance scanner, Germany) and symptom scale assessment before the first acupuncture stimulation and post the last acupuncture stimulation. Healthy volunteers receive only one scanning without intervention. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT02202486 -
Investigation of the Blood-brain and Blood-dura Barrier Durin Migraine Attacks Using MRI
|
N/A | |
| Completed |
NCT01687660 -
Acupuncture for Migraine Prophylaxis
|
N/A | |
| Completed |
NCT00363532 -
Functional MRI (fMRI) in CGRP Induced Migraine
|
N/A | |
| Completed |
NCT00123201 -
Study to Evaluate the Efficacy and Safety of Dronabinol Metered Dose Inhaler (MDI) in Acute Treatment of Migraine Headache
|
Phase 2 | |
| Completed |
NCT04406649 -
A Study to Evaluate the Safety of STS101 in the Acute Treatment of Migraine
|
Phase 3 | |
| Completed |
NCT03874832 -
A Phase I Study to Study the PK and Safety of Single Doses of STS101, DHE Injection and Nasal Spray in Healthy Subjects
|
Phase 1 | |
| Recruiting |
NCT05565001 -
The Involvement of ATP Sensitive Potassium Channel in Migraine Aura and Migraine Pain.
|
N/A | |
| Completed |
NCT04533568 -
Ibuprofen in Migraine Patients
|
Phase 4 | |
| Recruiting |
NCT05416476 -
Anisodine Hydrobromide For The Preventive Treatment Of Episodic Migraine
|
Phase 3 | |
| Completed |
NCT00534560 -
Dose Ranging Study of the Efficacy and Tolerability of Tonabersat in the Prophylaxis of Migraine Headache
|
Phase 2 | |
| Terminated |
NCT04936061 -
Transnasal Cooling for Migraine
|
N/A | |
| Recruiting |
NCT05281770 -
Monoclonal CGRP Antibodies for Migraine Prevention - a Nationwide Real Life Study
|
||
| Completed |
NCT00380263 -
PACAP38´s (Pituitary Adenylate Cyclase-Activating Polypeptide) Headache Inducing Characteristics and Effects on the Cerebral Blood Flow
|
N/A | |
| Completed |
NCT00334178 -
Evaluation of the Efficacy and Safety of Laxymig® as Prophylactic Treatment in Patients With Migraine
|
Phase 3 | |
| Recruiting |
NCT06051604 -
Mi-Helper Transnasal Cooling for Acute Treatment of Migraine
|
N/A | |
| Completed |
NCT03472378 -
Can DFN-15 Terminate Migraine With Allodynia?
|
Phase 2 | |
| Recruiting |
NCT05211154 -
Evaluation of the Efficacy of Diclofenac Potassium and Rimegepant for the Acute Treatment of Migraine
|
Phase 4 | |
| Recruiting |
NCT04157192 -
Brain Connectome for Acupuncture-treated Migraine Patients
|
N/A | |
| Completed |
NCT01471990 -
Effect of PACAP38/VIP on Migraineurs Measured by Magnetic Resonance
|
N/A | |
| Active, not recruiting |
NCT00285402 -
Efficacy and Safety Clinical Trial of Intranasal AST-726 for the Prevention of Migraine
|
Phase 2 |